Lurakem Study Quiz Link

The NMA study found that lurasidone had less somnolence compared to both Quetiapine and Ziprasidone. This means that lurasidone is associated with less drowsiness or sleepiness as a side effect compared to the other two medications. Therefore, the statement "lurasidone was having less somnolence compared to Quetiapine & Ziprasidone" is true based on the findings of the NMA study.

The NMA study found that lurasidone had better efficacy compared to both Aripiprazole and Ziprasidone. This suggests that lurasidone was more effective in treating the condition or symptoms being studied than the other two medications.

The statement suggests that in a long-term study of lurasidone, there were no significant changes observed in weight gain, BMI, glycemic indices, and prolactin levels. This implies that the use of lurasidone over a period of 2 years did not have a meaningful impact on these factors. Therefore, the answer "True" indicates that the statement is correct.

The statement "Lurasidone has high relapse rates" is false. This means that in the safety and efficacy study of lurasidone in the long term, lurasidone did not show high relapse rates.

CGI-BPS stands for Clinical Global Impression - Bipolar Scale. This scale is used in clinical research and practice to assess the severity of illness and overall improvement in patients with bipolar disorder. It involves rating the patient's condition on a scale from 1 to 7, with 1 indicating normal, not ill, and 7 indicating extremely ill. The CGI-BPS helps clinicians and researchers in evaluating the effectiveness of treatments and tracking the progress of patients with bipolar disorder.

The given statement is false. The NMA study shows that Olanzapine & Quetiapine had greater weight gain compared to Lurasidone.

The explanation for the given correct answer is that in a safety and efficacy trial conducted over a period of 2 years with lurasidone, the discontinuation rate due to adverse events was relatively low at 6.6%. This suggests that the participants in the trial were able to tolerate the medication well and did not experience significant adverse effects that would require them to discontinue its use. Therefore, the statement that discontinuation due to adverse events with lurasidone was relatively low as 6.6% is true.

The recent approval of Lurasidone from USFDA was for the indication of adolescent schizophrenia aged between 13-17.

The correct answer is the International Journal of Bipolar Disorder 2017.

The correct answer is "World Journal of Biological psychiatry 2017". This journal is likely to be the one where the NMA of Lurasidone Vs other antipsychotics was published, as it specifically focuses on biological psychiatry and publishes research in this field.